La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'La Jolla Pharmaceutical Company - Product Pipeline Review - 2016', provides an overview of the La Jolla Pharmaceutical Company's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company
- The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses La Jolla Pharmaceutical Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features La Jolla Pharmaceutical Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate La Jolla Pharmaceutical Company's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Company's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
La Jolla Pharmaceutical Company Snapshot 5
La Jolla Pharmaceutical Company Overview 5
Key Information 5
Key Facts 5
La Jolla Pharmaceutical Company - Research and Development Overview 6
Key Therapeutic Areas 6
La Jolla Pharmaceutical Company - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
La Jolla Pharmaceutical Company - Pipeline Products Glance 11
La Jolla Pharmaceutical Company - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
La Jolla Pharmaceutical Company - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
La Jolla Pharmaceutical Company - Drug Profiles 16
LJPC-501 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
LJPC-401 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LJPC-0712 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
LJPC-30Sa 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LJPC-30Sb 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LJPC-6417 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs for Undisclosed Indications 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
La Jolla Pharmaceutical Company - Pipeline Analysis 26
La Jolla Pharmaceutical Company - Pipeline Products by Target 26
La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration 27
La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type 28
La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action 29
La Jolla Pharmaceutical Company - Recent Pipeline Updates 30
La Jolla Pharmaceutical Company - Dormant Projects 33
La Jolla Pharmaceutical Company - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
GCS-100 34
LJPC-1010 34
La Jolla Pharmaceutical Company - Company Statement 35
La Jolla Pharmaceutical Company - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables

La Jolla Pharmaceutical Company, Key Information 5
La Jolla Pharmaceutical Company, Key Facts 5
La Jolla Pharmaceutical Company - Pipeline by Indication, 2016 7
La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016 9
La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016 10
La Jolla Pharmaceutical Company - Phase III, 2016 11
La Jolla Pharmaceutical Company - Phase I, 2016 12
La Jolla Pharmaceutical Company - Preclinical, 2016 13
La Jolla Pharmaceutical Company - Discovery, 2016 14
La Jolla Pharmaceutical Company - Unknown, 2016 15
La Jolla Pharmaceutical Company - Pipeline by Target, 2016 26
La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016 27
La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016 28
La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016 29
La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2016 30
La Jolla Pharmaceutical Company - Dormant Developmental Projects,2016 33
La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2016 34
La Jolla Pharmaceutical Company, Subsidiaries 37